Insider Trading Alert - AMRI, ULTI And MHFI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 13, 2014, 182 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $2,715,292,313,281.00.

Highlighted Stocks Traded by Insiders:

Albany Molecular Research (AMRI) - FREE Research Report

Marth William S, who is President and CEO at Albany Molecular Research, bought 30,000 shares at $15.40 on May 13, 2014. Following this transaction, the President and CEO owned 313,699 shares meaning that the stake was reduced by 10.57% with the 30,000-share transaction.

The shares most recently traded at $15.91, up $0.51, or 3.21% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 8,000

The average volume for Albany Molecular Research has been 682,100 shares per day over the past 30 days. Albany Molecular Research has a market cap of $497.6 million and is part of the health care sector and drugs industry. Shares are up 51.98% year-to-date as of the close of trading on Tuesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 51.3. Currently, there is 1 analyst who rates Albany Molecular Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders